Again, parents were not available for either the Capn5 nor Fblim1 CRISPR-edited mouse lines, so strain controls were examined.
Additionally, we also include verification of variants detected in the initial mouse line.
The key issue is that since parental lines were not available, might the reported variants have been inherited?
To expand upon the limited available whole genome data on whether CRISPR-edited mice show more genetic variation, whole-genome sequencing was performed on two other mouse lines that had undergone a CRISPR-editing procedure.
Taken together, these whole-genome-sequencing-level results support the idea that in specific cases, CRISPR-Cas9 editing can precisely edit the genome at the organismal level and may not introduce numerous, unintended, off-target mutations.
Our analytic research revealed that CRISPR/Cas9 has been utilized for millions of years by bacteria to edit their own genome (as a defense mechanism against virus); hence, it should be the safest of all platforms (like Zinc Finger Nuclease).
As follows, the stock traded $0.60 higher at $43.27 for 1.41% profits.